GlassScriptPhysician profile
Megan Holick
NPI 1346754199
$11,852.03
in general payments reported to CMS, 2019-2025
31 companies · $2,178 in 2025
The $2,178 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,599 · 2022: $2,314 · 2023: $2,528 · 2024: $3,234 · 2025: $2,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,669 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,668.99 |
| Education | $269.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,805.23 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,098.75 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $991.57 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $835.39 | 2021-2025 | |
| Lilly USA, LLC | $721.37 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Biotech, INC. | $589.03 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $571.58 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $553.07 | 2021-2025 | Opzelura, Opzelura |
| Ucb, INC. | $453.40 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $442.42 | 2021-2025 | Aklief |
| Sun Pharmaceutical Industries INC. | $390.95 | 2021-2025 | Ilumya, Blu-U |
| Pfizer INC. | $339.00 | 2022-2023 | |
| Amgen INC. | $296.85 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $278.05 | 2021-2025 | Adbry |
| Almirall LLC | $166.20 | 2022-2024 | Klisyri, Seysara |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.77 | 2022-2024 | Spevigo, Cyltezo |
| Organogenesis INC. | $144.55 | 2024 | |
| Genentech USA, INC. | $137.35 | 2021-2022 | |
| Biofrontera INC. | $137.14 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Stemline Therapeutics INC. | $104.87 | 2021 | |
| Genzyme Corporation | $102.73 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $98.55 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $93.96 | 2021-2023 | Arazlo |
| Mayne Pharma Commercial LLC | $80.79 | 2022-2023 | |
| Arcutis Biotherapeutics, INC. | $78.82 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $45.56 | 2022 | |
| Vyne Pharmaceuticals INC. | $35.59 | 2021 | |
| Organon LLC | $34.57 | 2024-2025 | Vtama |
| Mylan Institutional INC. | $21.07 | 2023 | |
| Hydrofera LLC | $20.89 | 2025 | Hydrofera Blue |
| Fresenius Kabi USA, LLC | $18.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Holick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.